The Antibiotic Pipeline: How an Economic Problem Became a Medical Crisis

Here's the timeline that should concern you. Alexander Fleming noticed bacterial growth inhibited by Penicillium mold in 1928. Penicillin entered clinical use in the early 1940s. The first penicillin-resistant bacteria were observed in clinical settings in 1942. That's roughly two years between "miraculous cure" and "this is already becoming a problem."

Fleming himself warned about this in his 1945 Nobel Prize lecture. He specifically cautioned that subtherapeutic doses of penicillin — doses too low to treat infection but enough to expose bacteria to the drug — would breed resistance. The medical and agricultural establishment spent the next seven decades doing almost exactly what he warned against.

## How resistance evolved

The mechanism is straightforward natural selection, and it's worth being precise about this rather than treating it as mysterious. Introduce an antibiotic into a bacterial population. Most bacteria die. The ones with mutations that happen to confer resistance survive and reproduce. Under continued antibiotic pressure, you're selecting for resistant strains. This has been observed happening in real time in clinical settings for eighty years. It's not a hypothesis.

The agricultural use of antibiotics created conditions for this process to operate at enormous scale. From the 1950s onward, livestock producers discovered that subtherapeutic doses of antibiotics produced faster growth in cattle, pigs, and poultry — the mechanism isn't fully understood, but the growth effect was economically significant. In the United States, agricultural antibiotic use reached roughly 80% of total antibiotic consumption by weight at its peak. This meant billions of bacteria were exposed to sub-lethal antibiotic concentrations for decades, creating ideal evolutionary pressure for resistance to develop and spread.

Resistant genes don't stay on farms. They travel via food, via water runoff, via direct animal contact, and via horizontal gene transfer between bacterial species — a mechanism by which bacteria can pass resistance traits to entirely different species. Resistance mechanisms developed in agricultural settings end up in pathogens that infect humans. The pathways are well-documented.

## The pipeline drought

Between roughly 1960 and 1990, the pharmaceutical industry produced a steady stream of new antibiotic classes. By the 1990s, this had largely stopped. The pipeline of new antibiotics in clinical development dried up dramatically over the following decade.

The economic logic is straightforward and depressing. A good antibiotic is taken for one to two weeks and cures the infection. A good drug for hypertension or type 2 diabetes is taken daily for decades. The revenue models are incomparable. A company investing a billion dollars in antibiotic development is looking at a market where, if the drug works well, physicians will actively try to use it sparingly — to preserve it, to delay resistance — which means it will be prescribed rarely, which means the manufacturer can't recoup the development cost.

You've created a product that, the better it is, the less it gets used. The incentive structure is perverse in a way that's genuinely hard to fix within a normal market framework.

The result: major pharmaceutical companies exited antibiotic development almost entirely in the early 2000s. Small biotech firms that remained frequently went bankrupt even after successfully bringing a new antibiotic through FDA approval. The science worked; the economics didn't.

## Where we are now

The WHO maintains a priority pathogens list — bacteria for which new antibiotics are urgently needed. The top tier includes carbapenem-resistant Enterobacteriaceae (CRE), Acinetobacter baumannii, and Pseudomonas aeruginosa. These are bacteria that cause serious infections, primarily in hospital settings, and are resistant to most or all available antibiotics. For some strains, physicians are already resorting to colistin — an antibiotic abandoned decades ago because of significant kidney toxicity — because there's nothing else in the approved arsenal.

Things are in development. Phage therapy — using bacteriophages, viruses that infect bacteria, to target specific pathogen strains — has been deployed on a compassionate-use basis in cases where all antibiotic options were exhausted. Some new antibiotic classes are in late-stage trials. CRISPR-based approaches targeting specific bacterial genetic sequences are theoretically promising. The science is genuinely interesting and moving forward.

The incentive problem, however, hasn't changed. Without either market reforms that make antibiotic development economically viable, or substantial direct public funding with guaranteed purchase commitments, the structural logic that drove pharma out of this space in the first place is still operating.

I'm not pessimistic about the science. The biology of resistance is understood well enough that we could respond more aggressively. I'm pessimistic about whether the economic structures that govern pharmaceutical development will change before the resistance situation gets substantially worse. The answer, at the moment, is unclear.

The Antibiotic Pipeline: How an Economic Problem Became a Medical Crisis

// COMMENTS

ON THIS PAGE